Signals, Powered By EquityPandit
Cipla‘s US arm InvaGen Pharmaceuticals Inc has got the final approval from the American health regulator for marketing generic Bupropion Hydrochloride extended release tablets that are used in the treatment of major depressive disorder.
Cipla has said in a statement that “InvaGen Pharmaceuticals Inc has received final approval for its abbreviated new drug application (ANDA) for Bupropion Hydrochloride extended release tablets (XL), 150 mg and 300 mg, from the United States Food and Drug Administration.”
It further said that the product is available for shipping immediately.
